MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
Psoriasis: Treatment and Pathogenesis
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,393 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,393 works in the cohort · of 4,299,418page 2 of 48

Labels cover 8 of 2,393 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,393 of 2,393 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
Psoriasis: classical and emerging comorbidities
Maria de Fátima Santos Paim de Oliveira, Bruno de Oliveira Rocha, Gleison Vieira Duarte
2015· review· en· Anais Brasileiros de Dermatologia· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
376
citations
fundno affno abstractunlabeled
Psoriasis: Which therapy for which patient
Shivani B. Kaushik, Mark Lebwohl
2018· review· en· Journal of the American Academy of Dermatology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
361
citations
affunlabeled
Signaling pathways and targeted therapies for psoriasis
Jia Guo, H. Zhang, Wenrui Lin, Lixia Lü, Juan Su, Xiang Chen
2023· review· en· Signal Transduction and Targeted Therapy· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
360
citations
affno abstractunlabeled
Obesity and the risk of psoriatic arthritis: a population-based study
Þorvarður Jón Löve, Yanyan Zhu, Yuqing Zhang, Lindsay Wall-Burns, Alexis Ogdie, Joel M. Gelfand +1 more
2012· article· en· Annals of the Rheumatic Diseases· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
306
citations
affno abstractunlabeled
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
Bruce Strober, Diamant Thaçi, Howard Sofen, Leon Kircik, Kenneth B. Gordon, Peter Foley +10 more
2022· article· en· Journal of the American Academy of Dermatology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
279
citations
affunlabeled
An update on generalized pustular psoriasis
Melinda Gooderham, Abby S. Van Voorhees, Mark Lebwohl
2019· review· en· Expert Review of Clinical Immunology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
221
citations
affno abstractunlabeled
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial
Richard G. Langley, Steven R. Feldman, Chenglong Han, Brad Schenkel, Philippe Szapary, Ming-Chun Hsu +3 more
2010· article· en· Journal of the American Academy of Dermatology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
216
citations
affgemma · no categorygpt · no categorymodels agree
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*
Richard B. Warren, Andrew Blauvelt, Yves Poulin, Stefan Beeck, Matt Kelly, Tianshuang Wu +2 more
2020· article· en· British Journal of Dermatology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
206
citations

How this was built: Screen · Findings · About